Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study

Martin Reck(LungenClinic Grosshansdorf), Stephen V. Liu(University of Southern California), Jong Seok Lee(Yonsei University), Maximilian J. Hochmair(Chinese University of Hong Kong), Barzin Y. Nabet(Gene Therapy Laboratory), Gregory J. Gerstner(Illinois CancerCare), Raffaele Califano(University of Manchester), Florian Huemer(Chinese University of Hong Kong), Marta Batus(Rush University Medical Center), György Losonczy(Chinese University of Hong Kong), Rafał Dziadziuszko(Gdańsk Medical University), Vaikunth Cuchelkar, Monika Kaul, Dariusz M. Kowalski(National Institute of Oncology), Bradford J. Danner, Shunichi Sugawara(Sendai Kousei Hospital), Gilberto de Castro(Twitter (United States)), Andrea Veatch(Northwest Medical Specialties), Zoran Andric(University Hospital Medical Center Bezanijska kosa), Steven Kao(Chris O’Brien Lifehouse), Huafei Li(Roche (China)), Stefanie Morris(Roche (Switzerland)), Libor Havel(Chinese University of Hong Kong)
Lung Cancer
August 10, 2024
10.1016/j.lungcan.2024.107924
Cited by 66

Related Papers

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k